Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model

By sjmartinez • October 16, 2023

Iannone V, Babu AF, Lok J, Gómez-Gallego C, D'Auria G, Vazquez-Uribe R, Vaaben TH, Bongers M, Mikkonen S, Vaittinen M, Tikkanen I, Kettunen M, Klåvus A, Sehgal R, Kaminska D, Pihlajamaki J, Hanhineva K, El-Nezami H, Alexander Sommer MO, Kolehmainen M. Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model. Mol Metab. 2023 Oct 13:101823. doi: 10.1016/j.molmet.2023.101823. Epub ahead of print. PMID: 37839774.

Tags: aldafermin, Cardiology/Epi, genetically modified E. coli Nissle 1917, Metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, non-targeted metabolomics, omics integration, Publications, Transcriptomics

Related Posts

The Cardiovascular Care of the Pediatric Athlete

Dean PN, Brothers JA, Burns K, Edelson JB, Etheridge S, Phelan DM, Shafer K, Snyder C, Molossi S, Danielian A, Friedman EM, Hsu J, Husaini[...]

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure with Reduced Ejection Fraction in a Safety-Net Healthcare System

DeJong C, Durstenfeld MS, Davis J, Wang CS, Chen J, Kazi DS, Hickey MD, Grochowski J, Steward WT, Riley ED, Zier LS, Moreau N, Huffman[...]